{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:28:53Z","timestamp":1793860133836,"version":"4.6.1"},"reference-count":29,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81230013 and 81530046"],"award-info":[{"award-number":["81230013 and 81530046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Antithymocyte globulin (ATG) is an important component of conditioning regimens to prevent severe graft\u2010versus\u2010host disease (GVHD) in patients undergoing unmanipulated, haploidentical stem cell transplantation (haplo\u2010SCT). However, to the authors' knowledge, the optimal dose of ATG is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>In this prospective, randomized trial, the authors compared the long\u2010term outcomes of 2 ATG doses (rabbit thymoglobulin) used in myeloablative conditioning before unmanipulated haplo\u2010HSCT. Patients were randomly assigned (1:1) to received 10\u2009mg\/kg (ATG\u201010) or 6\u2009mg\/kg (ATG\u20106) of ATG. Analysis of disease\u2010free survival, GVHD\u2010free\/recurrence\u2010free survival (GRFS), disease recurrence, nonrecurrence mortality, and chronic GVHD (cGVHD) included the entire population. Late effects were assessed in disease\u2010free patients who had survived for at least 6 months and had received regular follow\u2010up evaluations.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A total of 224 patients were recruited. The median follow\u2010up period was 1614 days (range, 28\u20101929 days). The rate of infection\u2010related deaths in ATG\u201010 arm was double that of the ATG\u20106 arm (14.3% vs 7.1%; <jats:italic>P<\/jats:italic>\u2009=\u2009.084). The 5\u2010year cumulative incidence was comparable between the ATG\u20106 and ATG\u201010 groups for disease recurrence (12.8% vs 13.4%; <jats:italic>P<\/jats:italic>\u2009=\u2009.832) and nonrecurrence mortality (11.6% vs 17.0%; <jats:italic>P<\/jats:italic>\u2009=\u2009.263). The 5\u2010year probability of disease\u2010free survival was comparable between the groups (75.6% vs 69.6%; <jats:italic>P<\/jats:italic>\u2009=\u2009.283). The 5\u2010year cumulative incidence of cGVHD was found to be higher with ATG\u20106 (75.0% vs 56.3% [<jats:italic>P<\/jats:italic>\u2009=\u2009.007] and moderate\u2010to\u2010severe cGVHD: 56.3% vs 30.4% [<jats:italic>P<\/jats:italic>&lt;.0001]) as well as that for late effects (71.2% vs 56.9%; <jats:italic>P<\/jats:italic>\u2009=\u2009.043). The 5\u2010year probability of GRFS was higher in the ATG\u201010 group (41.0% vs 26.8%; <jats:italic>P<\/jats:italic>\u2009=\u2009.008). In the multivariate analysis, ATG\u201010 was found to be associated with a lower risk of cGVHD and improved GRFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>ATG\u201010 was found to be associated with better GVHD prevention and superior GRFS, but an increase in infection\u2010related deaths. <jats:bold><jats:italic>Cancer<\/jats:italic> 2017;123:2881\u201392.<\/jats:bold> \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30540","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T16:53:33Z","timestamp":1489683213000},"page":"2881-2892","source":"Crossref","is-referenced-by-count":59,"title":["Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long\u2010term outcomes of a prospective randomized trial"],"prefix":"10.1002","volume":"123","author":[{"given":"Ying\u2010Jun","family":"Chang","sequence":"first","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010Dong","family":"Mo","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan\u2010Ping","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen\u2010Hua","family":"Yan","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng\u2010Rong","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing\u2010Zhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai\u2010Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010Jun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Peking University Institute of Hematology Beijing China"},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China"},{"name":"Peking\u2010Tsinghua Center for Life Sciences Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27761"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703674"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(03)00204-2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.191"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-418202"},{"key":"e_1_2_8_8_1","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa060185"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.01.026"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-609032"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70225-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00462-3"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3629"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.2942"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.04.007"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.135"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.223"},{"issue":"9","key":"e_1_2_8_21_1","first-page":"CD009159","article-title":"Polyclonal anti\u2010thymocyte globulins for the prophylaxis of graft\u2010versus\u2010host disease after allogeneic stem cell or bone marrow transplantation in adults","author":"Theurich S","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000133513.29923.44"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.06.014"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds615"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.306"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506002"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.3760\/cma.j.issn.0366-6999.20122752","article-title":"Risk factors for bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplantation","volume":"126","author":"Mo XD","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.4594"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23443"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563130"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:46:49Z","timestamp":1760273209000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":29,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1002\/cncr.30540"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30540","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]}}}